Eris Lifesciences

Eris Lifesciences

1,785.30
+17.00
(0.96%)
Market Cap
24,315.31 Cr
EPS
25.85
PE Ratio
68.65
Dividend Yield
0.42 %
Industry
Healthcare
52 Week High
1,910.00
52 Week Low
1,021.80
PB Ratio
8.42
Debt to Equity
0.97
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+90.00 %
+90.00 %
Hold
Hold+10.00 %
+10.00 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,692.00
#1 4,05,967.48
35.24
#1 54,729.00
12.06
#1 10,980
-18.99
52.71
6,618.50
1,75,700.38
80.64
9,712.00
0.89
2,191
23.05
42.75
1,487.90
1,20,178.85
23.13
28,409.50
7.12
5,291
30.28
49.20
3,519.90
1,19,129.41
62.79
11,539.40
11.59
1,911
10.91
65.81
2,589.50
1,06,876.11
61.82
12,744.20
19.57
2,007
-10.91
58.90
1,265.50
1,05,614.97
#1 18.77
33,741.20
16.73
5,725
1.26
47.24
971.25
97,730.48
20.83
23,511.00
13.82
4,615
-0.19
50.79
1,941.40
88,662.86
27.01
22,909.50
#1 19.94
3,306
#1 112.49
49.98
34,580.00
73,480.09
52.18
6,684.70
10.80
1,414
27.83
60.84
1,114.10
64,707.11
18.78
31,378.10
17.55
3,366
-0.50
43.00

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
19.85 %
Net Income Growth
6.12 %
Cash Flow Change
119.13 %
ROE
-26.88 %
ROCE
-14.45 %
EBITDA Margin (Avg.)
6.41 %

Quarterly Financial Results

Quarterly Financials
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
188
208
190
189
192
237
213
215
251
267
259
223
275
286
270
243
289
327
308
277
350
360
333
309
395
461
420
398
461
504
488
562
717
744
726
711
Expenses
109
125
112
135
114
152
128
141
162
164
159
153
170
175
190
171
189
205
203
184
223
220
210
209
269
309
286
284
297
324
311
403
470
477
477
453
EBITDA
79
83
78
54
78
86
85
75
88
103
100
70
105
111
81
72
100
122
105
93
127
141
123
100
125
151
134
114
164
180
177
160
248
267
249
258
Operating Profit %
40 %
37 %
39 %
27 %
39 %
34 %
38 %
32 %
34 %
37 %
36 %
28 %
38 %
38 %
28 %
30 %
34 %
37 %
33 %
33 %
35 %
38 %
36 %
31 %
31 %
32 %
32 %
28 %
35 %
35 %
36 %
26 %
34 %
35 %
34 %
36 %
Depreciation
5
5
6
7
5
5
7
9
7
8
10
11
12
12
13
14
10
11
11
12
15
15
17
18
23
29
30
35
41
42
46
54
76
81
81
77
Interest
0
1
0
0
0
0
3
8
7
6
5
4
1
1
0
0
0
0
0
1
1
1
1
1
7
7
3
9
17
16
18
33
60
60
57
54
Profit Before Tax
73
78
72
48
74
99
77
62
78
92
89
58
95
103
72
62
95
116
99
85
117
131
109
85
101
121
107
76
113
126
116
77
115
129
116
129
Tax
11
8
4
1
3
6
3
6
6
7
9
4
11
10
9
5
6
8
9
17
10
12
8
5
8
2
6
14
19
4
14
-3
26
33
29
27
Net Profit
63
69
68
47
71
93
75
56
72
86
80
54
84
93
64
56
89
108
90
68
107
118
101
80
93
119
100
62
94
122
102
80
89
96
87
102
EPS in ₹
45.64
5.02
4.95
3.43
5.15
6.75
5.43
4.06
5.18
6.20
5.83
3.93
6.11
6.74
4.62
4.13
6.56
7.93
6.64
5.03
7.86
8.71
7.41
5.91
6.96
8.84
7.49
4.81
6.97
9.08
7.55
5.22
6.11
6.73
6.16
6.90

Balance Sheet

Balance Sheet
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
398
727
1,460
1,554
1,552
1,835
2,272
3,667
7,041
7,033
Fixed Assets
65
232
771
761
875
854
918
2,568
4,319
5,307
Current Assets
237
216
299
582
480
467
627
765
2,302
1,223
Capital Work in Progress
0
0
0
3
4
2
27
22
20
67
Investments
144
303
365
356
78
294
520
37
16
67
Other Assets
190
192
324
435
595
685
807
1,041
2,686
1,593
Total Liabilities
398
727
1,460
1,554
1,552
1,835
2,272
3,667
7,041
7,033
Current Liabilities
71
76
226
306
165
167
200
443
2,532
1,381
Non Current Liabilities
25
60
349
79
91
91
164
1,003
1,286
2,380
Total Equity
302
591
886
1,169
1,296
1,576
1,908
2,221
3,222
3,272
Reserve & Surplus
302
553
848
1,137
1,283
1,563
1,894
2,182
2,573
2,841
Share Capital
0
14
14
14
14
14
14
14
14
14

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-2
4
-8
8
-3
60
-30
14
5
38
106
Investing Activities
-92
-44
-185
-590
-5
123
-323
-320
-975
-1,828
-78
Operating Activities
90
132
200
235
223
271
375
378
292
486
1,065
Financing Activities
1
-84
-24
363
-221
-335
-82
-45
688
1,380
-881

Share Holding

% Holding
Jan 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
55.55 %
54.13 %
52.69 %
52.68 %
52.66 %
52.66 %
52.30 %
52.29 %
52.70 %
52.86 %
52.86 %
54.91 %
54.90 %
54.90 %
54.88 %
54.87 %
54.86 %
54.85 %
54.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
13.20 %
0.00 %
14.27 %
14.59 %
8.01 %
8.35 %
8.43 %
8.40 %
DIIs
10.52 %
9.25 %
9.66 %
9.57 %
9.99 %
10.11 %
10.36 %
10.38 %
9.94 %
10.02 %
10.28 %
14.53 %
13.86 %
15.63 %
16.23 %
18.64 %
18.06 %
18.07 %
18.17 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
22.42 %
23.28 %
23.23 %
23.29 %
23.19 %
23.14 %
21.34 %
21.27 %
21.45 %
21.66 %
22.07 %
15.47 %
15.67 %
14.24 %
13.53 %
10.51 %
9.29 %
9.16 %
9.12 %
Others
11.51 %
13.34 %
14.42 %
14.46 %
14.16 %
14.09 %
16.01 %
16.07 %
15.90 %
15.46 %
14.79 %
1.90 %
15.57 %
0.95 %
0.77 %
7.96 %
9.43 %
9.49 %
9.47 %
No of Share Holders
29,195
41,470
46,477
49,833
54,223
57,061
51,639
48,055
46,746
45,931
44,169
42,245
46,496
51,753
44,176
46,346
53,314
50,087
52,225

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 2.87 5.5 6.01 7.35 0.00 7.35
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.47 0.8 1.05 0.87 0.00 0.42

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
25 Jul 2025 1,679.60 1,780.65
19 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
19 May 2025 1,402.05 1,465.15
13 Feb 2025 DIVIDEND Dividend
₹ 7.35 /share
13 Feb 2025 1,460.10 1,301.85
04 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
04 Feb 2025 1,157.90 1,248.00
25 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Oct 2024 1,329.15 1,282.30
25 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
25 Sept 2024 1,454.10 1,311.75
16 Aug 2022 DIVIDEND Dividend
₹ 7.35 /share
11 Aug 2022 696.65 695.05
06 Aug 2021 DIVIDEND Dividend
₹ 6.01 /share
05 Aug 2021 742.15 747.90

Announcements

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS3 days ago
Update To The Notice Convening The 19Th Annual General Meeting6 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Book Closure For Annual General MeetingJul 02, 2025
Shareholders Meeting - Annual General Meeting - July 25 2025Jul 02, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 02, 2025
Reg. 34 (1) Annual Report.Jul 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Board Meeting Outcome for The Meeting Held On June 30 2025Jun 30, 2025
Board Meeting Outcome for The Meeting Held On June 30 2025Jun 30, 2025
Closure of Trading WindowJun 27, 2025
Corporate PresentationJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2025
Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD Jun 09, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 04, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 19, 2025
Revision In Outcome Of Board MeetingMay 19, 2025
Financial Results For Quarter And Year Ended March 31 2025May 19, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025May 13, 2025
Update On Credit Rating Of Eris Therapeutics LimitedMay 09, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMay 09, 2025
Announcement Under Regulation 30 (LODR)-Credit Rating Of Eris Therapeutics LimitedMay 06, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMay 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 05, 2025
Corporate GuaranteeMar 31, 2025
Closure of Trading WindowMar 26, 2025
Clarification With Respect To Increase In VolumeMar 21, 2025
Clarification sought from Eris Lifesciences LtdMar 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 07, 2025
Announcement Under Regulation 30 - Sale Of SubsidiariesMar 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 06, 2025
Announcement Under Regulation 30 - Update On Acquisition Of 30% Equity Stake In Levim Lifetech Private LimitedFeb 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Announcement Under Regulation 30 - Redemption Of 43750 8% Secured Unlisted Redeemable Non-Convertible DebenturesFeb 21, 2025
Announcement Under Regulation 30 - Availing Credit FacilitiesFeb 21, 2025

Technical Indicators

RSI(14)
Neutral
61.54
ATR(14)
Less Volatile
56.30
STOCH(9,6)
Neutral
74.59
STOCH RSI(14)
Overbought
88.37
MACD(12,26)
Bullish
1.67
ADX(14)
Strong Trend
30.99
UO(9)
Bearish
47.88
ROC(12)
Uptrend But Slowing Down
2.96
WillR(14)
Overbought
-19.61

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
UTI Flexi Cap Fund Direct-Growth
0.88%
-97701
-0.04%
-0.01%
Franklin India Opportunities Direct Fund-Growth
1.10%
64376
0.16%
0.37%
HDFC Business Cycle Fund Direct - Growth
1.84%
62547
0.40%
1.84%
TRUSTMF Small Cap Fund Direct-Growth
1.68%
36634
0.60%
1.68%
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth
0.52%
29662
0.52%
0.52%
UTI Healthcare Fund Direct-Growth
2.75%
-25293
-0.30%
-0.19%
HSBC Small Cap Fund Direct-Growth
0.02%
22424
0.02%
0.02%
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth
0.52%
22210
0.52%
0.52%
Bank of India Consumption Fund Direct-Growth
2.73%
-13557
-0.45%
-0.15%
Bank of India Multi Asset Allocation Fund Direct-Growth
0.58%
12000
0.58%
0.58%
Aditya Birla Sun Life Equity Hybrid '95 Fund Direct-Growth
0.98%
-9665
0.02%
0.09%
Bandhan Small Cap Fund Direct-Growth
0.54%
-9000
-0.04%
-0.06%
Franklin India Flexi Cap Fund Direct-Growth
0.95%
-8846
0.02%
0.08%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
2.86%
-7929
-0.47%
1.73%
Bank of India Large & Mid Cap Fund Direct-Growth
2.73%
7414
0.33%
0.43%
Bank of India Manufacturing & Infrastructure Fund Direct-Growth
2.69%
-3902
-0.10%
-0.06%
Bank of India Midcap Tax Fund Series 1 Direct-Growth
1.20%
2500
0.65%
0.66%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.43%
2086
0.43%
0.43%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
1650
0.00%
0.01%
Quantum Small Cap Fund Direct - Growth
2.72%
-1597
-0.21%
-0.33%
Bandhan Nifty 500 Momentum 50 Index Fund Direct-Growth
0.52%
800
0.52%
0.52%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.45%
718
0.00%
0.01%
Franklin India Balanced Advantage Fund Direct - Growth
0.86%
-674
0.03%
0.03%
Franklin India Aggressive Hybrid Fund Direct-Growth
1.12%
-580
0.03%
0.11%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
327
0.00%
0.01%

About Eris Lifesciences

Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands and a distribution network of 22 sales depots, 2,059 stockists, and over 500,000 retail chemists. Eris has expanded through acquisitions and launches of new divisions. It has five wholly-owned subsidiaries and has acquired various brands and businesses in recent years, including dermatology and cosmetology brands. The company also produces human insulin and has entered the anti-thrombotics segment.
Listing Date
29 Jun, 2017(8 Years, -4 days)
Chairperson NameAmit Indubhushan Bakshi